Serum soluble Fas levels in patients with autoimmune rheumatic diseases.

摘要: Abstract Objective: The role of the serum soluble Fas (sFAS) system is unclear in diagnosis several autoimmune rheumatic diseases although there are present contradictory reports on levels sFas. We therefore assessed sFAS patients with diseases. Patients and methods: analyzed sFas their relationship to clinical laboratory data systemic lupus erythematosus (SLE, n = 32), rheumatoid arthritis (RA, n = 28), Sjogren's syndrome (SS, n = 20) sclerosis (SSc, n = 21), polymyositis/dermatomyositis (PM/DM, n = 15). osteoarthritis (OA, healthy volunteers (n = 20) were used as controls. Serum determined by ELISA. greater than mean (normals) + 2 SD considered elevated. Results: values found higher RA, PM/DM OA control no differences SSc SS patients. SLE lower Elevated rates be 21.4%, 60%, 10% controls, respectively. did not differ from values. Mean show significant difference between active inactive all disease groups except PM/DM, RA OA. No correlations relevant subsets, findings treatment modalities found. Conclusions: indicate that molecule may provide a useful additional marker for presence assessment PM/DM.